Trial Profile
A Phase 2 Open-label Clinical Trial Demonstrating the Safety of RBX2660 Microbiota Suspension for the Treatment of Recurrent Clostridium Difficile-associated Diarrhea (CDAD): the PUNCH CD Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jul 2023
Price :
$35
*
At a glance
- Drugs RBX 2660 (Primary)
- Indications Clostridium difficile infections; Diarrhoea
- Focus Adverse reactions
- Acronyms PUNCH-CD
- Sponsors Rebiotix
- 11 Jul 2023 According to a Ferring Pharmaceuticals media release, the integrated safety analysis of three phase 2 trials (PUNCH CD, PUNCH CD2, PUNCH Open-Label) and two phase 3(PUNCH CD3, PUNCH CD3-OLS) in Therapeutic Advances in Gastroenterology.
- 11 Jul 2023 Results presented in the Ferring Pharmaceuticals Media Release.
- 24 Oct 2022 Results presented in a Ferring Pharmaceuticals media release.